Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The collaboration will support Canada with direct access to rapid pandemic response capabilities
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
At the latest Indian Pharma Post E-Conference, leading experts identified faster regulatory approvals, infrastructure, digital innovation, investigator training, and public trust as critical pillars
The appointments come as Andrew Paterson, who has spent 31 years with the company, prepares to retire
Over the course of his career, he has also held leadership roles at Pfizer, Alembic Pharmaceuticals, and Cipla
In his new role, he will lead the company's growth strategy across Africa, strengthen healthcare partnerships, and expand access to innovative diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
